netFormulary Harrogate & Rural District Formulary NHS
Harrogate & District NHS Foundation Trust
Harrogate & Rural District Clinical Commissioning Group
 
 
 Search
 Formulary Chapter 8: Malignant disease and immunosuppression - Full Chapter
Notes:
All Chemotherapy in HDFT is prescribed using the ChemoCare electronic prescribing system.  Only Consultants or Registrars may initiate chemotherapy.

If any patients are admitted to the Trust on oral chemotherapy the admitting doctor must contact the Oncology/Haemtology team to determine whether the treatment should be continued.

If the original prescriber is not available or cannot be contacted the oral anticancer medicine must be not be prescribed or administered until it is confirmed that it is clinically appropriate and safe to do so.

Further guidance on oral chemotherapy can be found in the Oral Anti-Cancer Medicines Handbook on the Trust Intranet.

Guidance on symptom management in palliative care can be found in The Yorkshire Cancer Network and North East Yorkshire & Humber Clinical Alliance guidelines.

Chapter Links...
 Details...
08.01.05  Expand sub section  Other antineoplastic drugs
Cytotoxic Drug Aflibercept (Zaltrap®)
(25mg/ml concentrate for intravenous infusion)
View adult BNF View SPC online View childrens BNF  Track Changes
Restricted Drug Restricted
Red
Cancer Drugs Fund
NICE TA307: Aflibercept in combination with irinotecan and fluorouracil-based therapy for treating metastatic colorectal cancer that has progressed following prior oxaliplatin-based chemotherapy 
   
Cytotoxic Drug PembrolizumabBlack Triangle (Keytruda® )
View adult BNF View SPC online View childrens BNF  Track Changes
Restricted Drug Restricted
Red
High Cost Medicine
Cancer Drugs Fund
NHS England
BlueTeq
 
Link  NICE TA540 Pembrolizumab for treating relapsed or refractory classical Hodgkin lymphoma
   
Cytotoxic Drug Trifluridine / Tipiracil  (Lonsurf®)
(15mg/6.14mg or 20mg/8.19mg strength tablets)
View adult BNF View SPC online  Track Changes
Formulary
Red
NICE TA405: Trifluridine–tipiracil for previously
treated metastatic colorectal cancer 
   
08.01.05  Expand sub section  Amsacrine
08.01.05  Expand sub section  Arsenic trioxide
08.01.05  Expand sub section  Bevacizumab
Bevacizumab (Avastin®)
View adult BNF View SPC online View childrens BNF
Restricted Drug Restricted  
   
08.01.05  Expand sub section  Bexarotene to top
08.01.05  Expand sub section  Bortezomib
08.01.05  Expand sub section  Brentuximab vedotin
 note 

NICE TA446: Brentuximab vedotin for treating CD30-positive Hodgkin lymphoma

08.01.05  Expand sub section  Cetuximab
Cetuximab (Erbitux®)
View adult BNF View SPC online View childrens BNF
Restricted Drug Restricted  
Link  NICE TA439 - Cetuximab and panitumumab for previously untreated metastatic colorectal cancer
   
08.01.05  Expand sub section  Crisantaspase
08.01.05  Expand sub section  Dacarbazine and Temozolomide to top
08.01.05  Expand sub section  Erlotinib
08.01.05  Expand sub section  Hydroxycarbamide
Cytotoxic Drug Hydroxycarbamide
View adult BNF View SPC online View childrens BNF
Restricted Drug Restricted  
   
08.01.05  Expand sub section  Imatinib
08.01.05  Expand sub section  Mitotane
08.01.05  Expand sub section  Panitumumab to top
Panitumumab (®)
View adult BNF View SPC online View childrens BNF  Track Changes
Restricted Drug Restricted
Grey
High Cost Medicine
 
   
08.01.05  Expand sub section  Pentostatin
08.01.05  Expand sub section  Platinum compounds
Cytotoxic Drug Cisplatin
View adult BNF View SPC online View childrens BNF
Restricted Drug Restricted  
   
Cytotoxic Drug Oxaliplatin
View adult BNF View SPC online View childrens BNF
Restricted Drug Restricted  
   
08.01.05  Expand sub section  Porfimer sodium and temoporfin
08.01.05  Expand sub section  Procarbazine
08.01.05  Expand sub section  Protein kinase inhibitors to top
Dabrafenib (Tafinlar®)
View adult BNF View SPC online View childrens BNF  Track Changes
Formulary
Red
Patients are referred to Leeds Teaching Hospitals 
Link  NICE TA321: Dabrafenib for treating unresectable or metastatic BRAF V600 mutation-positive melanoma
   
Dasatinib (Sprycel®)
View adult BNF View SPC online View childrens BNF
Restricted Drug Restricted  
   
Erlotinib (Tarceva®)
View adult BNF View SPC online View childrens BNF
Restricted Drug Restricted  
   
Gefitinib (Iressa®)
View adult BNF View SPC online View childrens BNF
Restricted Drug Restricted  
   
Cytotoxic Drug Ibrutinib (Imbruvica®)
View adult BNF View SPC online View childrens BNF  Track Changes
Restricted Drug Restricted
Red
High Cost Medicine
Cancer Drugs Fund
Approved under the Cancer Drugs Fund, February 2015.

Available in 90 and 120 capsule pack-sizes 
Link  NICE TA 429
Link  NICE TA502
   
Nilotinib (Tasigna®)
View adult BNF View SPC online View childrens BNF
Restricted Drug Restricted  
   
08.01.05  Expand sub section  Tezanes
Cytotoxic Drug Paclitaxel
View adult BNF View SPC online View childrens BNF
Restricted Drug Restricted  
   
08.01.05  Expand sub section  Topoisimerase I inhibitors
08.01.05  Expand sub section  Trabectedin
08.01.05  Expand sub section  Trastuzumab
Cytotoxic Drug Trastuzumab (Herceptin®)
View adult BNF View SPC online View childrens BNF  Track Changes
Restricted Drug Restricted
Red
High Cost Medicine
 
   
Cytotoxic Drug Trastuzumab emtansine (Kadcyla® )
View adult BNF View SPC online View childrens BNF  Track Changes
Restricted Drug Restricted
Red
High Cost Medicine
Approved in February 2014 as per Cancer Drugs Fund (CDF)guidelines 
Link  TA458 - Trastuzumab emtansine for treating HER2-positive advanced breast cancer after trastuzumab and a taxane
   
08.01.05  Expand sub section  Tretinoin to top
Tretinoin
(10mg capsules)
View adult BNF View SPC online View childrens BNF  Track Changes
Restricted Drug Restricted
Red
One box stored in Pharmacy EMCU.
Out of Hours; please contact the on-call pharmacist 
Link  Guidelines for Acute Promyelocytic Leukaemia
   
08.01.05  Expand sub section  Vismodegib
 ....
 Non Formulary Items
Cytotoxic Drug  Amsacrine  (Amsidine®)

View adult BNF View SPC online View childrens BNF
Non Formulary
 
Cytotoxic Drug  Arsenic Trioxide  (Trisenox®)

View adult BNF View SPC online View childrens BNF
Non Formulary
 
Bexarotene  (Targretin®)

View adult BNF View SPC online View childrens BNF
Non Formulary
 
Bortezomib  (Velcade®)

View adult BNF View SPC online View childrens BNF
Non Formulary
 
Cytotoxic Drug  Carboplatin

View adult BNF View SPC online View childrens BNF
Non Formulary
 
Crisantaspase  (Erwinase®)

View adult BNF View SPC online View childrens BNF
Non Formulary
 
Cytotoxic Drug  Dacarbazine

View adult BNF View SPC online View childrens BNF
Non Formulary
 
Cytotoxic Drug  Docetaxel  (Taxotere®)

View adult BNF View SPC online View childrens BNF
Non Formulary
 
Erlotinib  (Tarceva® )

View adult BNF View SPC online View childrens BNF
Non Formulary
 
Everolimus  (Afinitor®)

View adult BNF View SPC online View childrens BNF
Non Formulary
 
Cytotoxic Drug  Imatinib  (Gilvec®)

View adult BNF View SPC online View childrens BNF
Non Formulary
 
Cytotoxic Drug  Irinotecan Hydrochloride  (Campto®)

View adult BNF View SPC online View childrens BNF
Non Formulary
 
Lapatinib  (Tyverb®)

View adult BNF View SPC online View childrens BNF
Non Formulary
 
Mitotane  (Lysodren®)

View adult BNF View SPC online View childrens BNF
Non Formulary
 
Cytotoxic Drug  Pentostatin  (Nipent®)

View adult BNF View SPC online View childrens BNF
Non Formulary
 
Porfimer Sodium

View adult BNF View SPC online View childrens BNF
Non Formulary
 
Cytotoxic Drug  Procarbazine

View adult BNF View SPC online View childrens BNF
Non Formulary
 
Sorafenib  (Nexavar®)

View adult BNF View SPC online View childrens BNF
Non Formulary
 
Sunitinib  (Sutent®)

View adult BNF View SPC online View childrens BNF
Non Formulary
 
Temoporfin  (Foscan®)

View adult BNF View SPC online View childrens BNF
Non Formulary
 
Cytotoxic Drug  Temozolomide  (Temodal®)

View adult BNF View SPC online View childrens BNF
Non Formulary
 
Cytotoxic Drug  Temsirolimus  (Torisel®)

View adult BNF View SPC online View childrens BNF
Non Formulary
 
Cytotoxic Drug  Topotecan  (Hycamtin®)

View adult BNF View SPC online View childrens BNF
Non Formulary
 
Cytotoxic Drug  Trabectedin  (Yondelis®)

View adult BNF View SPC online View childrens BNF
Non Formulary
 
  
Key
note Notes
Section Title Section Title (top level)
Section Title Section Title (sub level)
First Choice Item First Choice item
Non Formulary Item Non Formulary section
Restricted Drug
Restricted Drug
Unlicensed Drug
Unlicensed
Track Changes
Display tracking information
click to search medicines.org.uk
Link to adult BNF
click to search medicines.org.uk
Link to children's BNF
click to search medicines.org.uk
Link to SPCs
SMC
Scottish Medicines Consortium
Cytotoxic Drug
Cytotoxic Drug
CD
Controlled Drug
High Cost Medicine
High Cost Medicine
Cancer Drugs Fund
Cancer Drugs Fund
NHSE
NHS England
Homecare
Homecare
CCG
CCG

Traffic Light Status Information

Status Description

Amber

Medicines which are suitable to be prescribed in primary care only after specialist recommendation. Ongoing prescribing by primary care includes titration of dose and assessment of efficacy. There is no need for ongoing monitoring other than for general adverse effects as listed in the BNF & SPC.  

Amber Shared Care

Medicines which are suitable to be prescribed in primary care only after specialist recommendation only under a shared care protocol once the patient has been stabilised. Prior agreement must be obtained by the specialist from the primary care provider before prescribing responsibility is transferred. The shared care protocol must be approved by the Harrogate & Rurual District Area Prescribing Committee (HaRD APC).   

Black

Medicines which the Harrogate & Rural District Area Prescribing Committee (HaRD APC) has reviewed and does not recommend for use at present based on a review of clinical and/or cost effectiveness data.   

Green

Medicines suitable for routine use and can be prescribed within primary care within their licensed indication in accordance with nationally recognised formularies e.g. BNF, BNF for Children, Palliative Care Formulary. Primary care prescribers take full responsibility for prescribing.  

Grey

Medicines which the Harrogate & Rural District Area Prescribing Committee (HaRD APC) have not yet reviewed.   

Red

Medicines for hospital use only. The responsibility for initiation and monitoring treatment should rest with an appropriate hospital clinician. The drug should be supplied by the hospital for the duration of the treatment course. Primary care prescriber initiation or continuation of treatemnt is not recommended.  

netFormulary